Nuclea Biotechnologies Initiates Series C Round Targeting $10M | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies has started a Series C financing round targeting $10 million to further its regulatory submissions and for marketing activities, its CEO said today.

The company disclosed in a Form D filed this week with the US Securities and Exchange Commission that it had raised $1.9 million financing round. As a result, it has paid back a note held by six current shareholders in the firm, leaving Nuclea debt-free, CEO Patrick Muraca told GenomeWeb Daily News.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.